Khorana risk score
| . | Risk score . |
|---|---|
| Cancer type | |
| Very high risk: pancreatic, gastric | 2 |
| High risk: lung, lymphoma, gynecologic, bladder, testicular | 1 |
| Hematological markers | |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Patient factor | |
| Body mass index ≥35 kg/m2 | 1 |
| . | Risk score . |
|---|---|
| Cancer type | |
| Very high risk: pancreatic, gastric | 2 |
| High risk: lung, lymphoma, gynecologic, bladder, testicular | 1 |
| Hematological markers | |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Patient factor | |
| Body mass index ≥35 kg/m2 | 1 |
Adapted from Khorana et al.21